NetworkNewsBreaks – Kaival Brands Innovations Gr
Post# of 402
Kaival Brands (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has announced that Bidi(R) Vapor has received a PMTA acceptance letter from the U.S. Food and Drug Administration (“FDA”). Kaival is the exclusive global distributor of Bidi Vapor LLC products. The PMTA letter marks an important milestone Bidi’s overall application is one step closer to meeting the FDA’s baseline criteria before moving into the substantive review, which is the final phase of the PMTA process. The PMTAa for Bidi Vapor now move on to the filing review phase. The acceptance letter includes all 11 flavors in the Bidi Stick line of products. Bidi Vapor and Kaival Brands have been involved in a complete overhaul in product packaging, branding and labeling to meet and even exceed the industry standards and FDA guidelines and requirements. “We look forward to working with FDA during the filing and substantive review of the PMTAs, and further demonstrating the uncompromising product quality Bidi Vapor brings, as evidenced by our recent distribution announcement with H.T. Hackney,” says Kaival Brands COO Eric Mosser in the press release. “Moving to the filing and, we anticipate, to the substantive review phase of the PMTA process is where our months of extensive data collection, investment and hard work assembling 285,000 pages of science-based evidence will pay off.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer